Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
GPR52 comp-43 is an antagonist of G protein-coupled receptor 52 (GPR52; IC50 = 0.63 µM).1 It reduces mutant huntingtin (mHTT) protein levels in STHdhQ7/Q111 cells, a heterozygous in vitro model of Huntington's disease, in a concentration-dependent manner. GPR52 comp-43 (3 µM) reduces apoptosis induced by growth factor deprivation in primary striatal neurons isolated from the heterozygous HdhQ7/Q140 mouse model of Huntington's disease. It decreases striatal levels of soluble and insoluble mHTT, as well as increases the latency to fall in the rotarod test, in the homozygous HdhQ140 mouse model of Huntington's disease, when administered at a dose of 5 mg/kg.
WARNING This product is not for human or veterinary use.
1. GPR52 antagonist reduces huntingtin levels and ameliorates Huntington’s disease-